11.27.12
Dr. Prasad Raje has been appointed vice president of science and technology at Cambridge Major Laboratories. Dr. Raje will provide technical and strategic leadership and will have overall responsibility for the company’s API development organization. He will also play a key role in implementing new technologies and services.
Dr. Raje has more than 15 years of pharmaceutical industry experience and a track record of providing substantial organizational growth. He previously served as president of Smithers Pharma Services, a CRO with expertise in analytical services, pharmaceutical R&D, and agrochemicals. Dr. Raje also held positions with AMRI, initially as section head, chemical development, and later as president and managing director of AMRI India.
“Dr. Raje brings a proven track record of solving the most complex chemistry challenges relating to the development of APIs, solid state chemistry, formulation development, and analytical chemistry,” said Brian Scanlan, president and chief executive officer of CML. “His in-depth knowledge across the entire drug development process will help guide our clients’ development programs from early pre-clinical through to commercialization, said Scanlan. His passion for chemistry will expand our culture of innovation and technical excellence, cementing our leading position in the industry.”
Dr. Raje has more than 15 years of pharmaceutical industry experience and a track record of providing substantial organizational growth. He previously served as president of Smithers Pharma Services, a CRO with expertise in analytical services, pharmaceutical R&D, and agrochemicals. Dr. Raje also held positions with AMRI, initially as section head, chemical development, and later as president and managing director of AMRI India.
“Dr. Raje brings a proven track record of solving the most complex chemistry challenges relating to the development of APIs, solid state chemistry, formulation development, and analytical chemistry,” said Brian Scanlan, president and chief executive officer of CML. “His in-depth knowledge across the entire drug development process will help guide our clients’ development programs from early pre-clinical through to commercialization, said Scanlan. His passion for chemistry will expand our culture of innovation and technical excellence, cementing our leading position in the industry.”
